Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CAMP4 THERAPEUTICS CORPORATION

Healthcare US CAMP

4.17USD
0.19(4.77%)

Last update at 2026-06-03T20:00:00Z

Day Range

3.934.22
LowHigh

52 Week Range

1.307.75
LowHigh

Fundamentals

  • Previous Close 3.98
  • Market Cap234.16M
  • Volume48399
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-50.42200M
  • Revenue TTM3.50M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM -34.70400M
  • Diluted EPS TTM-2.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-02-28 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-02-28 2022-12-31
Income before tax -80.40300M -51.79100M -49.29100M -31.33900M -44.19200M
Minority interest - - - - -
Net income -80.40300M -51.79100M -49.29100M -32.49000M -44.19200M
Selling general administrative 17.36M 14.92M 11.61M 51.82M 10.23M
Selling and marketing expenses - - 29.52M 47.39M 47.39M
Gross profit 1.86M 0.65M 0.35M 109.01M 109.01M
Reconciled depreciation 1.64M 1.70M 1.68M 21.76M 0.88M
Ebit -52.06100M -53.08800M -51.87900M -21.48200M -45.00100M
Ebitda -50.42200M -51.39200M -50.20100M 0.28M -44.12300M
Depreciation and amortization 1.64M 1.70M 1.68M 21.76M 0.88M
Non operating income net other - - - -0.39400M -
Operating income -52.06100M -53.08800M -51.87900M -21.48200M -45.00100M
Other operating expenses 55.56M 53.74M 52.23M 315.05M 45.00M
Interest expense - - 4.66M 6.26M 6.26M
Tax provision - - - 1.15M -
Interest income 2.17M 1.33M 2.81M - 0.90M
Net interest income 2.17M 1.33M 2.81M -6.26000M 0.90M
Extraordinary items - - - - -
Non recurring - - - 4.59M -
Other items - - - - -
Income tax expense - - -0.52500M 1.15M 1.15M
Total revenue 3.50M 0.65M 0.35M 294.95M 294.95M
Total operating expenses 53.92M 53.74M 52.23M 129.11M 45.00M
Cost of revenue 1.64M - 119.25M 185.94M 185.94M
Total other income expense net -28.34200M 1.30M 2.59M -9.85700M 0.81M
Discontinued operations - - - - -
Net income from continuing ops -80.40300M -51.79100M -49.29100M -32.49000M -44.19200M
Net income applicable to common shares - - - -32.49000M -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2024-02-29 2023-12-31 2023-02-28
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2024-02-29 2023-12-31 2023-02-28
Total assets 117.81M 78.31M - 54.95M 380.12M
Intangible assets - - - - 26.63M
Earning assets - - - - -
Other current assets 4.42M 2.24M - 1.19M 26.02M
Total liab 70.10M 15.16M - 178.68M 365.81M
Total stockholder equity 47.70M 63.14M - -123.73000M 14.31M
Deferred long term liab - - - - -
Other current liab 5.66M 4.92M - 3.71M 27.63M
Common stock 0.00600M 0.00200M - 0.00100M 0.37M
Capital stock 0.00600M 0.00200M - 0.00100M 0.37M
Retained earnings -292.15600M -211.75300M - -159.96200M -168.81600M
Other liab - - - - -
Good will - - - - 94.21M
Other assets - - - - -
Cash 109.52M 64.04M - 38.38M 41.93M
Cash and equivalents - - - - -
Total current liabilities 15.51M 9.60M - 7.81M 106.50M
Current deferred revenue 9.39M 0.39M - - 25.45M
Net debt -107.54300M -55.39100M - -26.68700M 198.51M
Short term debt 0.29M 3.08M - 3.06M 0.70M
Short long term debt - - - - 0.70M
Short long term debt total 1.97M 8.65M - 11.69M 240.44M
Other stockholder equity 339.85M 274.89M - 36.23M 184.67M
Property plant equipment - - - - 32.83M
Total current assets 114.09M 66.38M - 40.01M 174.79M
Long term investments - - - - -
Net tangible assets - - - - -106.54000M
Short term investments - - - - -
Net receivables 0.15M 0.11M - 0.44M 82.95M
Long term debt - - - - 227.42M
Inventory - - - - 23.90M
Accounts payable 0.18M 1.21M - 1.04M 52.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - 0.00000M -1.92300M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.37M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -168.81600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 1.62M - 1.62M 36.08M
Deferred long term asset charges - - - - -
Non current assets total 3.71M 11.92M - 14.93M 205.32M
Capital lease obligations 1.97M 8.65M - 11.69M 12.31M
Long term debt total - - - - 227.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-02-28 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-02-28 2022-12-31
Investments - -0.44100M -0.67800M -11.10000M -4.02500M
Change to liabilities - - - 17.32M -
Total cashflows from investing activities -0.24300M -0.44100M -0.67800M -11.10000M -4.02500M
Net borrowings -0.11100M -0.36400M -0.32200M - -0.09300M
Total cash from financing activities 75.89M 71.66M 0.30M -0.90900M 100.16M
Change to operating activities - - - - -
Net income -80.40300M -51.79100M -49.29100M -32.49000M -44.19200M
Change in cash 46.09M 25.66M -44.53200M -37.29300M 83.19M
Begin period cash flow 65.66M 40.00M 84.54M 79.22M 26.95M
End period cash flow 111.76M 65.66M 40.00M 41.93M 110.14M
Total cash from operating activities -29.55300M -45.56200M -44.15500M -22.93200M -38.54300M
Issuance of capital stock 57.52M 76.35M 0.00000M - 100.19M
Depreciation 1.64M 1.70M 1.68M 21.76M 0.88M
Other cashflows from investing activities 0.04M - - - -
Dividends paid - - - - -
Change to inventory - - - -5.77200M -5.77200M
Change to account receivables - - - -21.73400M -21.73400M
Sale purchase of stock - - - - -
Other cashflows from financing activities 14.93M 72.49M 0.18M -1.86500M 100.25M
Change to netincome - - - 10.96M -
Capital expenditures 0.28M 0.44M 0.68M 11.10M 4.03M
Change receivables - - - -21.73400M -
Cash flows other operating - - - -46.61300M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -34.94100M -
Change in working capital 13.01M -1.88400M -0.15400M -25.06500M 0.37M
Stock based compensation 4.00M 4.03M 2.91M 10.21M 1.38M
Other non cash items 32.20M 2.38M 0.70M 1.98M 3.02M
Free cash flow -29.83200M -46.00300M -44.83300M -34.03200M -42.56800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
CAMP
CAMP4 THERAPEUTICS CORPORATION		 0.19 4.77% 4.17 - - 66.94 4.90 36.05
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CAMP4 THERAPEUTICS CORPORATION

One Kendall Square, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Mr. Jeffery R. Gardner Pres, CEO & Director 1960
Mr. Anand Rau Sr. VP & CTO 1963
Ms. Xiaolian Zhang Sr. VP of Financial Planning & Analysis and Acting CFO NA
Scott Tripp VP of Operations NA
Mr. Erik Schulz VP, Corp. Controller & Interim Chief Accounting Officer 1971
Mr. Richard Scott Sr. VP, Chief Legal Officer & Sec. 1970
Mr. Mark Gaydos Chief Marketing Officer NA
Ms. Monica D. Van Berkel Sr. VP & Chief People Officer 1969
Mr. Richard K. Vitelle Exec. VP 1954
Mr. Michael P. Zachan Sr. VP & GM of Wireless Networks Bus. Unit 1949

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions